Michael Hayden, MBCHB (M.D.), Ph.D., Lead Director at AbCellera Biologics Inc.. Biography, career history and compensation sourced from SEC proxy filings.
About
Dr. Michael Hayden has served on AbCellera's Board of Directors since September 2019 and is the Lead Director, Chair of the Compensation Committee and a member of the Audit and Nominating and Corporate Governance Committees. He has been CEO of Prilenia Therapeutics B.V. since September 2018 and was previously Chief Scientific Officer and President of Global R&D at Teva Pharmaceutical Industries (2012-2017). He founded several biotechnology companies, including Xenon Pharmaceuticals and 89bio, and serves on the boards of Ionis Pharmaceuticals and 89bio. A Killam Professor of Medical Genetics at the University of British Columbia, he holds an M.B., Ch.B. (M.D.) and a Ph.D. in Genetics from the University of Cape Town.
Roles
AbCellera Biologics Inc.
Lead Director · Current role
September 2019–present
Teva Pharmaceutical Industries Ltd.
Chief Scientific Officer and President of Global R&D
September 2012 - December 2017
Xenon Pharmaceuticals Inc.
Founder; Director
November 1996 - June 2022
External Roles
Prilenia Therapeutics B.V.
Chief Executive Officer
September 2018 - present
Ionis Pharmaceuticals Inc.
Director
September 2018 - present
89bio, Inc.
Director
April 2018 - present
University of British Columbia
Killam Professor of Medical Genetics
—
Director Compensation
FY 2025
Fees earned or paid in cash
$110,000
ComponentBoard (Lead Director / committee) cash retainers earned in FY2025
Option awards
$476,361
ComponentAnnual stock option grant, ASC 718 grant-date fair value